We are thrilled to announce the closing of BioAge's IPO! As of September 26, we are trading on Nasdaq as $BIOA. This milestone will enable our development of novel therapies that treat metabolic diseases by harnessing the biology of aging. Heartfelt thanks to the BioAge team for their brilliance and dedication, and to the investors and partners who believed in our vision and supported us on our journey. Together, they made this day possible. As we look to the future, we will continue to advance innovative treatments for the most prevalent and pressing health challenges of our time. Here’s to the next chapter, and to longer, healthier lives for all! Details: https://lnkd.in/g9kyj6xT
BioAge Labs
生物技术研究
Richmond，CA 14,406 位关注者
We are harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases.
关于我们
BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses >65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.
- 网站
-
https://bioagelabs.com/
BioAge Labs的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Richmond，CA
- 类型
- 私人持股
- 创立
- 2015
- 领域
- aging、longevity和biotechnology
地点
-
主要
获取路线
1445A S 50th St
US，CA，Richmond，94804
BioAge Labs员工
动态
-
?? BioAge CEO & co-founder Kristen Fortney has been recognized as a “Cardiometabolic All-Star” in the 2024 PharmaVoice 100, a list that salutes biotech leaders who are leading in transformational times for the industry and forging new paths for others to follow. “Fortney’s breakthrough insight — that the mechanisms governing aging are linked to the pathogenesis of age-related diseases —?fits neatly into the wider goals of obesity drug development, and could lead to therapies that restore body composition and boost metabolism overall.” https://lnkd.in/dQzracmz
-
The BioAge podcast, Translating Aging, features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!
“We're opening up the epigenome as a platform for drug discovery.” Moonwalk Biosciences is a biotech company devoted to pioneering precision epigenetic medicines. This week on Translating Aging, CEO & co-founder Alex Aravanis MD PhD tells us about Moonwalk’s mission to harness the power of epigenetics to develop a new class of medicines aimed at treating complex diseases and potentially extending human healthspan. Translating Aging is produced by BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Episode: https://lnkd.in/g6XtThZK (click ‘FOLLOW’ for links to your favorite podcast platform) Podcast: https://lnkd.in/gvF4X-ka
-
-
On Wednesday September 25th, BioAge’s VP-Translational Aging Biology Yan Wang will speak at Biocytogen’s Bay Area forum on “Robust In Vivo Models: De-Risking Clinical Trials.” In her talk, Yan will share how our translational in vivo studies catalyzed the clinical development of our lead product candidate, the APJ agonist azelaprag, currently in a Phase 2 clinical trial for obesity. Register for this in-person event here: https://lnkd.in/g9Ccypns
?? Dive into Innovation at Gene-ius Break Forum in South SF! ?? Join us on September 25th in South San Francisco for the Gene-ius Break Forum— a unique event where insightful speeches take the spotlight, complemented by complimentary food, drinks, and invaluable networking opportunities! These exciting presentations add immense value to this exceptional event. After the talks, savor delicious food and drinks while networking with industry leaders. Don’t miss this rare opportunity to gain insights, spark new ideas, and be part of something truly extraordinary—RSVP today! ??? Date: Wednesday, September 25th · 4pm - 8pm PDT ?? Location: Tower Place, 1 Tower Pl, South San Francisco, CA 94080 RSVP here: https://lnkd.in/eWHbVtwS #Biocytogen #HappyHour #SouthSF #Networking #Innovation #Biotech
此处无法显示此内容
在领英 APP 中访问此内容等
-
Tonight at the Aging Research & Drug Discovery Meeting , BioAge CBO & Head of Brain Aging Peng Leong joined a panel of luminaries to discuss the dense connections between early-stage development in longevity biotech and the broader pharma sector. Their wide-ranging conversation encompassed the concepts at the very foundation of longevity biotech, the challenges of translating geroscience into the clinic, and how they envision the future of drug discovery and development at the intersection of aging biology and disease. ??What are the optimal indications for clinical trials? ??How do earlier-stage biotechs get to know potential pharma partners? ??What is pharma looking for in the biotech startups they partner with? ??Where are the opportunities to be grasped - and the pitfalls to be avoided? Many thanks to amazing moderator Michael Ringel of Boston Consulting Group (BCG) for his thoughtful and incisive questions, and to the stellar panelists - David Glass (Regeneron), Johan Luthman (Lundbeck), Jonathan Wilson (Eli Lilly and Company), and Alex Zhavoronkov (Insilico Medicine) - for a fascinating discussion!
-
-
Action shot! Naisha S., BioAge's VP-Data Science, giving her talk entitled "Targeting aging biology: exercise induced pathways for the treatment of metabolic disease" on the main stage at the Aging Research & Drug Discovery Meeting in Copenhagen.
-
-
At the Aging Research & Drug Discovery Meeting in Copenhagen today, our VP of Data Science Naisha S. gave a talk on drug target discovery for metabolic disease?at the intersection of exercise and aging. Her presentation showcased how how BioAge analyzes human longevity data to identify exercise-induced pathways, underpinning our mission to develop therapies for metabolic diseases.
-
-
We are delighted to welcome Sangita Ghosh, PhD as BioAge's new Senior Vice President of Chemistry, Manufacturing, and Controls (CMC). With over two decades of experience in pharmaceutical development and a track record of bringing multiple drugs to market, Dr. Ghosh will be instrumental as we progress our lead candidate, azelaprag, through clinical trials. Great to have you on the team, Sangita!
-
-
BioAge is proud to sponsor the 2024 Aging Research & Drug Discovery Meeting , the 11th in a series that has grown into the essential annual conference for the longevity biotech sector and our collaborators in academic and pharma. Kicking off today in Copenhagen ???? —?looking forward to seeing all of our friends & colleagues who will be attending!
-